Medical routine, not disease, now drives much of the risk for many older adults. New guidance from geriatric researchers argues that several once standard interventions should be scaled back when life expectancy shrinks and competing illnesses dominate. At the top of the list are aggressive cancer screening, tight glucose targets in type 2 diabetes, and automatic repeat bone density tests that rarely change care.
Cancer screening, researchers say, can become a poor bargain. Colonoscopy, mammography and prostate tests expose patients to bleeding, false positives and invasive biopsies, while the benefit depends on years of lead time that many frail patients no longer have. Risk–benefit models and randomized trial follow‑ups show diminishing mortality gains when severe heart failure, advanced lung disease or dementia already dictate prognosis.
Even more overrated, in the view of many endocrinologists, is strict glycemic control late in life. Intensive insulin or sulfonylurea regimens aimed at very low HbA1c values increase hypoglycemia, falls and hospital admissions. Geriatric guidelines now endorse de‑intensification and higher glucose targets, especially for people on multiple drugs, a practice meant to cut polypharmacy and protect functional status rather than chase textbook numbers.
Bone density testing also loses power as a blanket habit. Dual‑energy X‑ray absorptiometry can identify osteoporosis, yet repeated scans at short intervals often leave fracture risk estimates unchanged while adding cost and anxiety. Researchers recommend focusing on prior fractures, corticosteroid exposure and gait instability instead, reserving scans for cases where the result would actually alter decisions on bisphosphonate or other antiresorptive therapy.
